• Significant regulatory and commercial progress for SibnayalTM
• Control of expenses with a net loss reduced to €12.4 million (vs. €14.8 million)
• Closing cash position at €12.7 million.
• • Commercial launch of SibnayalTM in Europe expected in 2022.

Paris, 31 March 2022 – 6.00 pm CET – Advicenne (Euronext: ALDVI), a pharmaceutical company specializing in the development and commercialization of innovative treatments for those suffering from rare renal diseases, today announces the publication of its financial results for the year ended 31 December 2021 and provides an update on its activities.

The audited financial statements for the year 2021 were approved by the Board of Directors at its meeting on March 31, 2021.